ライフサイエンスコーパス: acute liver failure

1 cids in the neurological complications after acute liver failure.

2 etaminophen overdose is the leading cause of acute liver failure.

3 or the importance of these variants in human acute liver failure.

4 for regenerative therapies for APAP-induced acute liver failure.

5 es, hepatitis E may lead to life-threatening acute liver failure.

6 side analogue (fialuridine [FIAU]) developed acute liver failure.

7 damage, a paradigm for glutathione-mediated acute liver failure.

8 es of drug induced liver injury resulting in acute liver failure.

9 rum cytokine assays 12 h after initiation of acute liver failure.

10 r data in consecutive patients admitted with acute liver failure.

11 ression was reduced by recAP in ACLF but not acute liver failure.

12 ric patients with end-stage liver disease or acute liver failure.

13 atment option for prevention of ACLF but not acute liver failure.

14 Keratin variants may predict outcome of acute liver failure.

15 gan dysfunction and outcome in patients with acute liver failure.

16 dysfunction syndrome and improve outcome in acute liver failure.

17 ated injury and systemic inflammation during acute liver failure.

18 n toxicity among subjects with indeterminate acute liver failure.

19 s may be an effective treatment modality for acute liver failure.

20 ver injury (DILI), chronic liver disease, or acute liver failure.

21 ty factor shown to predispose to HAV-induced acute liver failure.

22 pathy-sparing, specific and novel therapy in acute liver failure.

23 r disease which in some instances has led to acute liver failure.

24 complications independently associated with acute liver failure.

25 enerative process in liver diseases, such as acute liver failure.

26 efit patients with non-acetaminophen-related acute liver failure.

27 s with early stage non-acetaminophen-related acute liver failure.

28 minophen (APAP) overdose is a major cause of acute liver failure.

29 bclinical cardiac injury might also occur in acute liver failure.

30 siRNA resulted in the early onset of lethal, acute liver failure.

31 e intensive care management of patients with acute liver failure.

32 y been reported for adults and children with acute liver failure.

33 ly modulated even in late-stage APAP-induced acute liver failure.

34 The treatment was not effective in acute liver failure.

35 ovel regenerative therapies for APAP-induced acute liver failure.

36 Group 3 animals declined rapidly, with acute liver failure.

37 tions that lead to generalized infection and acute liver failure.

38 therapeutic option to treat posthepatectomy acute liver failure.

39 ey contributing factor for cerebral edema in acute liver failure.

40 ining diet before azoxymethane (AOM)-induced acute liver failure.

41 hat can lead to herpes simplex virus-induced acute liver failure.

42 making in patients with paracetamol-induced acute liver failure.

43 ytokine assays showed pronounced features of acute liver failure 12 h after application of acetaminop

44 Of 165 children admitted with pediatric acute liver failure, 136 met the inclusion criteria and

45 were 11 catastrophic events (early deaths or acute liver failures; 2.9 per 1000; 95% CI, 1.5-5.1); si

46 In patients with acetaminophen-induced acute liver failure, a low serum level of CSF1 was assoc

47 Acetaminophen-induced acute liver failure (AALF) is associated with innate imm

48 Acetaminophen-induced acute liver failure (AALF) is characterized both by acti

49 xicity accounts for 41%; among children with acute liver failure, acetaminophen was the second most c

50 from 78 patients with acetaminophen-induced acute liver failure admitted to the Royal Infirmary Edin

51 on in alcoholic liver disease (8.3-24.0) and acute liver failure (ALF) (5.9-7.6).

52 a concentrations are common in patients with acute liver failure (ALF) and are associated with hepati

53 ival was also analyzed by underlying disease-acute liver failure (ALF) and chronic liver failure.

54 eration, overwhelming liver damage can cause acute liver failure (ALF) and death without emergent liv

55 hose adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephal

56 a multicenter cohort of adult patients with acute liver failure (ALF) and in an acetaminophen (APAP)

57 Specific efficacious therapies for acute liver failure (ALF) are limited and time-dependent

58 Mechanisms of brain edema in acute liver failure (ALF) are not completely understood.

59 Twelve percent of all acute liver failure (ALF) cases are of unknown origin, o

60 yzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post

61 Acute liver failure (ALF) due to drug-induced liver inju

62 Acute liver failure (ALF) due to Wilson disease (WD) is

63 BACKGROUND & AIMS: Patients with acute liver failure (ALF) have defects in innate immune

64 BACKGROUND DATA: Patients with severe acute liver failure (ALF) have extreme physiologic dysfu

65 BACKGROUND & AIMS: Patients with acute liver failure (ALF) have high mortality and freque

66 paracetamol) poisoning is a leading cause of acute liver failure (ALF) in humans and induces hepatocy

67 Acute liver failure (ALF) in infancy and childhood is a

68 virus (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries,

69 ification accuracy of an e-Nose in detecting acute liver failure (ALF) in rats.

70 inophen toxicity is the most common cause of acute liver failure (ALF) in the United States and Great

71 Medications are a major cause of acute liver failure (ALF) in the United States, but no p

72 acetaminophen (APAP) is the leading cause of acute liver failure (ALF) in the United States.

73 Acute liver failure (ALF) induced by diffuse metastatic

74 Acute liver failure (ALF) is a devastating clinical synd

75 Acute liver failure (ALF) is a devastating syndrome affl

76 Hepatitis B virus (HBV)-associated acute liver failure (ALF) is a dramatic clinical syndrom

77 Acute liver failure (ALF) is a prototypical syndrome of

78 Acute liver failure (ALF) is a rare but challenging clin

79 Acute liver failure (ALF) is a rare syndrome of severe,

80 Acute liver failure (ALF) is associated with massive hep

81 Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant

82 Pediatric acute liver failure (ALF) is life threatening with genet

83 ying autoimmune hepatitis as the etiology of acute liver failure (ALF) is potentially important, beca

84 Mortality of patients with acute liver failure (ALF) is still unacceptably high.

85 Acute liver failure (ALF) is uncommon but progresses rap

86 Drug-induced and indeterminate acute liver failure (ALF) might be due to an autoimmune-

87 type is the most suitable source of CBTs for acute liver failure (ALF) or chronic liver failure (CLF)

88 Patients who have acute liver failure (ALF) or require an acute retranspla

89 the central nervous system in patients with acute liver failure (ALF) present unique challenges in t

90 develop severe acute liver injury (sALI) or acute liver failure (ALF) remain little known.

91 Acute liver failure (ALF) remains a disease with poor pa

92 Brain edema in acute liver failure (ALF) remains lethal.

93 Acute liver failure (ALF) represents a life-threatening

94 its rarity, it represents the major cause of acute liver failure (ALF) requiring liver transplantatio

95 eptibility to developing sepsis is common in acute liver failure (ALF) resulting in tissue damage and

96 om acetaminophen (APAP, paracetamol)-induced acute liver failure (ALF) showed significant differences

97 (HBV) infection remains a frequent cause of acute liver failure (ALF) worldwide.

98 patients with acute liver dysfunction (e.g. acute liver failure (ALF), acute-on chronic liver failur

99 ride (LPS) and concanavalin A (ConA)-induced acute liver failure (ALF), but the mechanism by which FK

100 Acute liver failure (ALF), characterized by sudden onset

101 ransplant centers coordinate complex care in acute liver failure (ALF), for which liver transplant (L

102 injury or arrhythmias have been reported in acute liver failure (ALF), overall, the heart is conside

103 ten serious in pregnancy and could result in acute liver failure (ALF).

104 action, is used widely to determine risk for acute liver failure (ALF).

105 minophen (APAP) overdose is a major cause of acute liver failure (ALF).

106 gnized and potentially fatal complication of acute liver failure (ALF).

107 l liver support device, may be beneficial in acute liver failure (ALF).

108 sure are potentially lethal complications of acute liver failure (ALF).

109 lantation currently exists for patients with acute liver failure (ALF).

110 liver disease (CLD) is required to diagnose acute liver failure (ALF).

111 hypertension and mortality in patients with acute liver failure (ALF).

112 injury models in mice, and in patients with acute liver failure (ALF).

113 Acetaminophen toxicity is a leading cause of acute liver failure (ALF).

114 d out in a patient with dengue virus induced acute liver failure (ALF).((1)) Their report highlights

115 asma of patients with acute liver injury and acute liver failure (ALI/ALF).

116 ucing intracranial pressure in patients with acute liver failure and cerebral edema.

117 n of AAT can be a promising therapy to treat acute liver failure and clinical studies to explore this

118 on in 24 patients with acetaminophen-induced acute liver failure and compared with 10 healthy control

119 tor of TGFbeta1 signaling during AOM-induced acute liver failure and contributes to both liver pathol

120 tation into mice with concanavalin-A-induced acute liver failure and fatal metabolic liver disease du

121 strophic consequences to the graft including acute liver failure and graft loss.

122 Acetaminophen (APAP) overdose results in acute liver failure and has limited treatment options.

123 aim of this study was to assess TSP-1 during acute liver failure and HE pathogenesis.

124 e injected with azoxymethane (AOM) to induce acute liver failure and HE.

125 Severe hepatic insults can lead to acute liver failure and hepatic encephalopathy (HE).

126 is the most frequent precipitating cause of acute liver failure and liver transplant, but contempora

127 ara-aminophenol [APAP]) is the main cause of acute liver failure and liver transplantation in several

128 ially attractive method for the treatment of acute liver failure and liver-based metabolic disorders.

129 nificantly elevated in acetaminophen-induced acute liver failure and non-acetaminophen induced acute

130 onic hyperammonemia animal models, including acute liver failure and ornithine transcarbamylase defic

131 otoxin) is implicated in the pathogenesis of acute liver failure and several chronic inflammatory liv

132 inophen overdose is the most common cause of acute liver failure and the leading cause of chronic liv

133 ll focus on the current approach to neonatal acute liver failure and the progress made in the diagnos

134 enol [APAP]) is one of the leading causes of acute liver failure, and APAP hepatotoxicity is associat

135 Hypoxemia is a feared complication of acute liver failure, and high oxygen requirements will f

136 Young children with rapid onset acute liver failure are a high-risk subpopulation.

137 HSV-1 generalized infections and subsequent acute liver failure are less well understood.

138 me of acute respiratory distress syndrome in acute liver failure are scant and hypoxemia being a comm

139 ients with liver-based metabolic disease and acute liver failure as a potential alternative to liver

140 ceptor 9 expression in acetaminophen-induced acute liver failure being mediated both by circulating e

141 r the management of individual patients with acute liver failure, but also to improve the uniformity

142 Treatment of acute liver failure by cell transplantation is hindered

143 d intracranial hypertension in patients with acute liver failure by decreasing splanchnic ammonia pro

144 Acute liver failure can be associated with rapidly progr

145 Drug-induced acute liver failure can be caused by many drugs routinel

146 Life-threatening acute liver failure can be triggered by a variety of fac

147 n confirm that of the approximately 1600 new acute liver failure cases annually, acetaminophen hepato

148 analgesic responsible for more than half of acute liver failure cases.

149 We describe a case of acute liver failure caused by echovirus 25 (E25) in a pr

150 ine seems to be beneficial for patients with acute liver failure caused by medications or herbal agen

151 lase concentrations in acetaminophen-induced acute liver failure compared with controls (p < 0.05).

152 d in all patients with acetaminophen-induced acute liver failure compared with healthy controls (p <

153 or autoimmune hepatitis) or patients without acute liver failure (controls) collected from a DILI Bio

154 and 2017 because of ALF defined by Pediatric Acute Liver Failure criteria (raised transaminases, Inte

155 atients with life-threatening liver disease (acute liver failure, decompensated cirrhosis, or severe

156 tracranial pressure monitor in acetaminophen acute liver failure did not confer a significant 21-day

157 commonly available on admission in cases of acute liver failure due to APAP overdose and should be v

158 outcome in a well-established mouse model of acute liver failure during septic shock.

159 nd stabilize the lost metabolic function for acute liver failure, end-stage and congenital liver dise

160 In these regions it is an important cause of acute liver failure, especially in pregnant women who ha

161 at Angiopoietin-2 protein was upregulated in acute liver failure explants compared with matched liver

162 imate the risk of perioperative mortality or acute liver failure for live liver donors in the United

163 ence of existing liver disease distinguishes acute liver failure from decompensated cirrhosis or acut

164 osing cholangitis, neonatal hemochromatosis, acute liver failure (from the Pediatric Acute Liver Fail

165 brain herniation are major complications of acute liver failure (fulminant hepatic failure) and a ma

166 identify information related to drug-induced acute liver failure, gastrointestinal hypomotility, cons

167 aware of common drug causes of drug-induced acute liver failure, gastrointestinal hypomotility, cons

168 veloped severe laboratory abnormalities, and acute liver failure has been reported (Table ).

169 Because of its rarity, acute liver failure has not been studied in large, rando

170 Although animal models of acute liver failure have been established, the study of

171 Hepatitis B virus (HBV)-related acute liver failure (HBV-ALF) may occur after acute HBV

172 1) has been shown to contribute to HE during acute liver failure; however, TGFbeta1 must be activated

173 ing 30 Argentinean patients with HAV-induced acute liver failure in a case-control, cross-sectional,

174 18-associated severe systemic infection and acute liver failure in an adult hematopoietic stem cell

175 Acute liver failure in children was shown to differ in s

176 ed model of lipopolysaccharide (LPS)-induced acute liver failure in D-galactosamine (GalN)-sensitized

177 es, who presented with recurrent episodes of acute liver failure in early infancy and are affected by

178 Acetaminophen (APAP) overdose causes acute liver failure in humans and rodents due in part to

179 Because it is among the common causes of acute liver failure in intensive care units and in light

180 ay represent a therapeutic strategy to treat acute liver failure in mice.

181 that ameliorates the effects of APAP-induced acute liver failure in the mouse and therefore may provi

182 rdose is a major cause of hepatotoxicity and acute liver failure in the U.S., but the pathophysiology

183 erdose is one of the most frequent causes of acute liver failure in the United States and is primaril

184 ry (DILI) is among the most common causes of acute liver failure in the United States, accounting for

185 (APAP) overdose is the predominant cause of acute liver failure in the United States.

186 ylenol, is the leading cause of drug-induced acute liver failure in the United States.

187 ity is the most common drug-induced cause of acute liver failure in the United States.

188 of the leading causes of hepatotoxicity and acute liver failure in the United States.

189 Acetaminophen (APAP) is the main cause of acute liver failure in the West.

190 ; APAP) overdose is the most common cause of acute liver failure in the Western world, with limited t

191 liver injury and the most frequent cause of acute liver failure in the Western world.

192 terile cell death and the commonest cause of acute liver failure in the western world.

193 acetaminophen (APAP) is the leading cause of acute liver failure in the Western world.

194 phen (APAP) overdose is the leading cause of acute liver failure in Western countries.

195 APAP) overdose is the most frequent cause of acute liver failure in young adults in the United States

196 y is associated with modulating pathology in acute liver failure, in liver regeneration, and in the m

197 Causes of acute liver failure include paracetamol toxicity, hepati

198 Acute liver failure initiates a sterile inflammatory res

199 ntracranial pressure monitored patients with acute liver failure, intracranial hypertension is common

200 process that occurs after liver injury, but acute liver failure is a complex and fatal disease which

201 Acute liver failure is a potentially devastating clinica

202 Acute liver failure is a rare and severe consequence of

203 Acute liver failure is a rare disorder with high mortali

204 Acute liver failure is divided into hyperacute, acute an

205 usceptibility to development of ACLF whereas acute liver failure is likely due to direct hepatoxicity

206 ized, and its pathogenesis in the context of acute liver failure is unclear.

207 mine-induced osmotic swelling, especially in acute liver failure, is a contributing factor: the osmot

208 rtality benefit, whereas in nonacetaminophen acute liver failure, it may be associated with worse out

209 s in patients with WD who have progressed to acute liver failure, leaving liver transplantation as th

210 Patients with paracetamol-induced acute liver failure managed at intensive care units in t

211 of therapeutic hypothermia in patients with acute liver failure, multicenter, randomized, controlled

212 luded patients with nonacetaminophen-induced acute liver failure (n = 13), nonhepatic multiple organ

213 irrhosis without decompensation (n = 17), or acute liver failure (n = 23).

214 Acute liver failure not caused by paracetamol was associ

215 compartment syndrome must be suspected when acute liver failure occurs in patients with subcapsular

216 Intracranial hypertension in patients with acute liver failure often can be temporarily controlled

217 were measured in sera from 37 patients with acute liver failure on admission and from 20 healthy con

218 ssion was increased in acetaminophen-induced acute liver failure on day 1 compared with healthy contr

219 all patients recovered without experiencing acute liver failure or chronic liver injury.

220 vides an excellent outcome for patients with acute liver failure or complications of end-stage liver

221 te attack in acute intermittent porphyria or acute liver failure or end-stage chronic liver disease i

222 Liver failure, whether arising directly from acute liver failure or from decompensated chronic liver

223 rated in patients with acetaminophen-induced acute liver failure (p = 0.042) at the time of liver tra

224 Pediatric acute liver failure (PALF) is a potentially devastating

225 y between children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in

226 (APAPo) is predominant in the NIH Pediatric Acute Liver Failure (PALF) Study.

227 cranial pressure monitoring in patients with acute liver failure, patient selection and ancillary ass

228 continuous renal replacement therapy use in acute liver failure patients and to assess its impact on

229 l, pulmonary, and endocrine complications of acute liver failure patients are provided, including the

230 liver failure and non-acetaminophen induced acute liver failure patients compared with multiple orga

231 Acute liver failure patients receiving mechanical ventil

232 Two hundred acute liver failure patients were admitted during the st

233 In a prospective, double-blind trial, acute liver failure patients without clinical or histori

234 ergent practices and a paucity of studies in acute liver failure patients, additional information was

235 iated with reduced ammonia concentrations in acute liver failure patients.

236 nagement of intracranial hypertension in non-acute liver failure patients.

237 useful approach to hyperammonemia control in acute liver failure patients.

238 early phases of human acetaminophen-induced acute liver failure, peaking on day 1 of hospital admiss

239 amine the influence of acetaminophen-induced acute liver failure plasma and endogenous DNA on Toll-li

240 ls were incubated with acetaminophen-induced acute liver failure plasma with and without deoxyribonuc

241 upon stimulation with acetaminophen-induced acute liver failure plasma, which was abrogated by prein

242 In drug-induced acute liver failure, plasma levels correlate with outcom

243 rough the critical period for survival after acute liver failure, providing promising clues of integr

244 Few conditions are known to cause recurrent acute liver failure (RALF), and in about 50% of cases, t

245 The mechanisms that drive irreversible acute liver failure remain poorly characterized.

246 Acute liver failure remains a critical clinical conditio

247 ause of liver injury in 14% of patients with acute liver failure remains unknown (indeterminate).

248 tive or detrimental in acetaminophen-induced acute liver failure remains unknown.

249 liver transplantation in paracetamol-induced acute liver failure require re-evaluation.

250 erdose represents the most frequent cause of acute liver failure, resulting in death or liver transpl

251 Patients with acute liver failure should be maintained in a mildly hyp

252 plantation of hiPSC-EB-HLC in a rat model of acute liver failure significantly prolonged the mean sur

253 rospectively collected cases of all forms of acute liver failure since 1998.

254 ntation, used in nearly 30% of patients with acute liver failure, still provides a life-saving altern

255 only measured clinical variables (called the Acute Liver Failure Study Group [ALFSG] index) and compa

256 minate, and drug-induced ALF patients in the Acute Liver Failure Study Group from 1998-2007.

257 males), who met the criteria defined by the "Acute Liver Failure Study Group Germany".

258 The Acute Liver Failure Study Group has prospectively collec

259 which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought to standardiz

260 similar prognostic power as the established Acute Liver Failure Study Group index (C-statistic 0.87

261 late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early,

262 sorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014).

263 ions, sera from 110 subjects enrolled in the Acute Liver Failure Study Group registry with indetermin

264 measured in 187 patients enrolled in the US Acute Liver Failure Study Group registry, and correlated

265 m samples of 681 adults enrolled in the U.S. Acute Liver Failure Study Group were tested for anti-HEV

266 sis, acute liver failure (from the Pediatric Acute Liver Failure Study Group), and liver transplantat

267 The U.S. Acute Liver Failure Study Group, comprised of 33 tertiar

268 Acute Liver Failure Study Group.

269 In acute liver failure, subclinical myocardial injury appea

270 Well-established preclinical models of acute liver failure such as the Jo2 FAS/CD95 activating

271 potentially life-threatening complication of acute liver failure, the syndrome of abrupt loss of live

272 ovide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study

273 sity for patients with acetaminophen-induced acute liver failure to develop sepsis, which may culmina

274 agement of patients with paracetamol-induced acute liver failure to identify those needing emergency

275 ly in critically ill children with pediatric acute liver failure to provide stability and bridge to t

276 nin I levels may be helpful in patients with acute liver failure, to detect unrecognized myocardial d

277 , aripiprazole for MI, and telithromycin for acute liver failure) using Medicaid Analytic eXtracts (f

278 with neostigmine diminishes liver damage in acute liver failure via the cholinergic anti-inflammator

279 Median age of patients with acute liver failure was 34 yrs, 29 were female, and 21 d

280 The ensuing acute liver failure was characterized by serological, hi

281 Acute liver failure was induced in BALB/c mice by a toxi

282 Acute liver failure was induced with Galactosamine-LPS a

283 lure Study Group registry with indeterminate acute liver failure were analyzed with a similar but mor

284 tes from patients with acetaminophen-induced acute liver failure were assessed for apoptosis-associat

285 nuous renal replacement therapy in pediatric acute liver failure were changed in 2011 following preli

286 Patients with acute liver failure were excluded from the analysis.

287 Usual causes of acute liver failure were excluded, all drugs were stoppe

288 Children with pediatric acute liver failure were managed according to a set prot

289 ARDS and acute liver failure were more frequent in the Acinetobac

290 ty-eight patients with acetaminophen-induced acute liver failure were recruited.

291 Peak levels in patients with acute liver failure were seen at admission then fell sig

292 responses prevail during the later stages of acute liver failure where elevated levels of M30 are lik

293 evalence of lung injury is relatively low in acute liver failure, where 21% fulfilled acute respirato

294 a greatly enhanced Th1 cytokine response and acute liver failure, which mechanistically depended on T

295 s should be administered to any patient with acute liver failure who develops signs of the systemic i

296 Among children with pediatric acute liver failure who did not receive a liver transpla

297 lar fatty infiltration of hepatocytes causes acute liver failure with coagulopathy and encephalopathy

298 ells to be transplanted intraperitoneally in acute liver failure with the advantage of avoiding immun

299 liver injury (DILI) is an important cause of acute liver failure, with limited therapeutic options.

300 standardize the management of patients with acute liver failure within participating centers.